The company has begun establishing partnerships with medical centers for a large prospective study of its test for identifying aggressive tumors.
In PNAS this week: optical mapping study of multiple myeloma, role for miR-204 in form of retinal dystrophy, and more.
In Science this week: microRNA expression as marker for injury due to radiation exposure, and more.
Prolias accused PDI of breaching a joint venture agreement to validate, commercialize, and monetize Prolias' miRNA thyroid cancer test. PDI denied liability and said it would defend itself vigorously.
Cancer-ID is a newly created consortium tasked with validating blood-based biomarkers, such as CTC, cfDNA, and miRNA to bring liquid biopsies into the clinic.
In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.
The investment bank upgraded Rosetta's shares following the completion of the firm's purchase of PersonalizeDx earlier in the week.
With the support of an NIH grant, Nawgen aims to create assays covering all microRNAs in the human and mouse genomes.
A fourth paper from MIT's Robert Weinberg has been retracted, according to Retraction Watch.
The study indicates that miRNAs act as genomic noise dampeners, controlling variability in protein expression.
Following its departure from the European Union, the UK is to implement a fast-track visa program aimed at attracting scientific talent to Britain, according to BBC News.
ScienceInsider reports that researchers in Brazil are concerned that a creationist was chosen to run the agency that oversees graduate study programs there.
The Washington Post reports that researchers are quickly analyzing the coronavirus that has been causing illness and sharing their findings.
In PLOS this week: common variant associated with BMI in Arctic populations, analysis of microRNA markers associated with being born small for gestational age, and more.